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Abstract
Background:  Clinical trials throughout the world must be evaluated by research ethics
committees. No one has yet attempted to clearly quantify at the national level the activity of ethics
committees and describe the characteristics of the protocols submitted. The objectives of this
study were to describe 1) the workload and the activity of Research Ethics Committees in France,
and 2) the characteristics of protocols approved on a nation-wide basis.
Methods: Retrospective cohort of 976 protocols approved by a representative sample of 25/48
of French Research Ethics Committees in 1994. Protocols characteristics (design, study size,
investigator), number of revisions requested by the ethics committee before approval, time to
approval and number of amendments after approval were collected for each protocol by trained
research assistant using the committee's files and archives.
Results: Thirty-one percent of protocols were approved with no modifications requested in 16
days (95% CI: 14–17). The number of revisions requested by the committee, and amendments
submitted by the investigator was on average respectively 39 (95% CI: 25–53) and 37 (95% CI: 27–
46), per committee and per year. When revisions were requested, the main reasons were related
to information to the patient (28%) and consent modalities (18%). Drugs were the object of
research in 68% of the protocols examined. The majority of the research was national (80%) with
a predominance of single-centre studies. Workload per protocol has been estimated at twelve and
half hours on average for administrative support and at eleven and half hours for expertise.
Conclusion: The estimated workload justifies specific and independent administrative and financial
support for Research Ethics Committees.
Background
Clinical trials in biomedical research throughout the
world must be evaluated by research ethics committees.
No one has yet attempted to clearly quantify the activity
of ethics committees and describe the characteristics of
the protocols submitted, and only five studies[1-4] have
dealt with this subject, two in England and the others in
the USA, Australia and Spain. However, they each focused
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on only one or two research ethics committees, and no
knowledge is available on a national or even a regional
level. In addition, four of these studies[2-4] concentrated
on the fate of protocols; some characteristics were gath-
ered but they were presented only for protocols whose
investigator was not lost to follow-up. None of these stud-
ies evaluated research ethics committees' workload, but
one study[1] described the activity in terms of number of
meetings, approvals and reasons of queries.
France was one of the first country to affirm these princi-
ples through the Huriet-Sérusclat Act of 1988 [5], which
launched administrative and financially independent
research ethics committees (REC) in 1991, called CCP-
PRBs (committees for the protection of human beings
involved in biomedical research). Each protocol involving
human beings in France has to be assessed by one of these
committees.
A European harmonization was needed since a long time
and was decided in 2001 [6]. All European governments
were asked to change national laws according to this
directive. Research ethics committees will be created
where they do not exist currently and it is of upmost
importance to anticipate activity, workload, financial and
administrative support needed by these committees.
We describe one year of activity in a sample comprising
half of the French RECs and the full characteristics of the
protocols approved in these RECs during this year.
Methods
All biomedical research protocols approved by a repre-
sentative random sample of every other French RECs the
participating committees between 01 January 1994 and
31 December 1994 were included. This year was chosen in
order to allow studies to be completed and so to collect
data on all amendments, information and serious adverse
effects.
Definitions
The definitions used in this study are drawn from French
law on the subject (table 1).
Data collection
Ethics committee activity and protocol characteristics
were gathered into four thematic groups. The first two
comprised committee activities: (i) the process of
approval (modifications requested before approval,
approval date, etc.), (ii) the modifications requested after
approval and the information transmitted. The other two
comprised protocol characteristics: (iii) the legal and
administrative characteristics of protocols (investigator,
sponsor, etc.) and (iv) the proposed scientific characteris-
tics (duration, sample size, etc.). Research assistants in
charge of data collection were trained in order to ensure
homogeneous results. The questionnaires were completed
using the committee's archives, and were then sent to the
coordinating centre. An identification number was given
to each protocol in order to ensure anonymity of the
investigator.
Assessment of activity and expertise workload
Activity
Each formal step was studied, i.e., the number of proto-
cols approved, revisions requested by the ethics
committee and amendments submitted by the investiga-
tor were studied. The number of revisions, amendments
Table 1: Definitions
Area covered by the law Every trial or experimentation involving human beings based on a procedure formalized in a protocol 
in order to develop biological or medical knowledge.
CCPPRB "Comités Consultatifs de Protection des Personnes se Prêtant à la Recherche Biomédicale", i.e., 
committees for the protection of human beings involved in biomedical research.
Composition of REC The committees gather 12 members and 12 replacements. The REC is made up of four persons 
competent in biomedical research (at least three physicians), a general practitioner, two pharmacists 
(at least one working in a hospital, a nurse, one person qualified in ethics, one social worker, one 
person qualified in psychology and one person qualified in the legal aspects of research.
Studies without direct individual benefit None of the participants could expect any individual and immediate benefit, e.g. research in physiology 
or phase I studies are typically considered as studies with no therapeutic benefit for subjects.
Studies with direct individual benefit Patients can potentially expect a therapeutic benefit from the research.
Decision RECs have four possibilities in their decisions: rejecting the protocol, accepting the protocol without 
any modifications, accepting the protocol with minor modifications or asking for revisions (major 
modifications) before approval.
Time to decision RECs must give their first answer within 5 weeks after the protocol application.
Revision Mandatory modification requested by the REC before protocol approval.
Amendment Modifications proposed by the investigator to the committee after approval
Information Investigators can send information concerning their study (state of inclusions, article, etc.). This 
information does not lead to a decision by the REC.BMC Medical Ethics 2005, 6:9 http://www.biomedcentral.com/1472-6939/6/9
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and total exchanges (defined as the sum of revisions and
amendments) were calculated per approved protocol.
Administrative and expertise load
At the REC level, each protocol is registered and assessed
for approval. A list of the different tasks was established by
the Lyon B REC members and administrative staff and
submitted to a national panel of REC members (table 2).
The time required to accomplish each task was estimated
based on individual experience and checked on site. For
this study, the estimated times devoted to administrative
work and expert assessment were then accepted by con-
sensus among administrative staff and REC members
respectively. The workload is estimated from a protocol
perspective, i.e. each protocol is valued. We did not assess
neither fix activities, such as or training of the members or
structure management (accounting, legal, insurances,
structure organisation,...), nor the committee meetings.
Statistics
As this was mainly a descriptive study, we presented fre-
quency distributions calculated with SAS software®. A
Kaplan-Meier survival analysis [7] was performed with
SPSS software® to establish probability of approval curves
based on cumulative hazard function in order to study the
time between the submission of the protocol and final
approval (in days). A log-rank test [7] was then computed
to compare protocols with direct approval, protocols with
minor modifications and protocols with revisions.
A multiple correspondence analysis [8] was also per-
formed on protocol characteristics. To determine the
number of axes we used the scree test [9] and the total
inertia was computed with Benzecri formulae [10]. To
explain the meaning of each axis, modalities of variables
were cumulated until 80% of inertia was explained. The
individual coordinates were then used to obtain a hierar-
chical clustering with the Ward minimum variance
Table 2: Development of REC activities
Main tasks administrative time (h) expert time (h)
New file Receipt 0.25 0.25
Computer registration 0.25 0,25
Content and conformity checking 1 1
Acknowledgement of receipt 0.5 -
Sending to the experts 0.5 -
Inscription of committee's meeting agenda 0.5 -
Sending the reply ready for posting 1 -
Filing 0.5 0.5
Valuation+writing and sending valuer's report - 4
TOTAL NEW FILE 4.5 6
Revision Request for information to the investigator 1 -
Disfiling 0.5 0.5
Reply receipt 0.5 0.25
Sending to the experts 0.5 -
Inscription of committee's meeting agenda 0.5 -
Sending the reply ready for posting 1 -
Filing 0.5 0.5
Valuation+writing and sending valuer's report - 2
TOTAL REVISION 4.5 3.25
Amendment Receipt 0.5 0.5
Disfiling 0.5 0.5
Sending to the experts 0.5 -
Inscription of committee's meeting agenda 0.5 -
Writing and sending the reply 1 -
Filing 0.5 0.5
Valuation+writing and sending valuer's report - 1
TOTAL AMENDMENT 3.5 2.5
-: not applicableBMC Medical Ethics 2005, 6:9 http://www.biomedcentral.com/1472-6939/6/9
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method [11]. The number of clusters was chosen using the
cubic clustering criterion [12].
To compare number of revisions, amendments and time
per protocol between the clusters an ANOVA was per-
formed [13].
Results
A total of 25/48 RECs throughout France participated in
this national study. There were 1143 declared protocols
approved by these committees during the year 1994. One
hundred sixty-seven had to be excluded because the inclu-
sion criteria were not fulfilled (Table 3). Thus 976 proto-
cols were eligible (mean per committee, 39; median, 37;
range, 17–81).
REC activity
Approval
Only 31% of protocols were approved with no request for
modifications. Minor or major modifications were
requested for the remaining protocols.
Time from submission of application to approval
Because of missing registration and/or approval dates,
seven protocols were dropped from the study, and the
analysis was performed on 969 studies. The median time
to approval for protocols with direct approval, with minor
changes requested, and request for major changes (revi-
sions) was, respectively, 16 days (95% confidence inter-
val: 14–17), 27 days (24–30) and 48 days (43–52). The
comparison between the three groups resulted in a signif-
icant log-rank test (figure 1).
Number of modifications studied
On average, the number of revisions required was 39 per
committee and per year (median, 30; range, 4–132, 95%
CI, 25–53) and the number of amendments was 37
(median, 28; range, 3–91, 95% CI, 27–46). Thus the aver-
age number of exchanges (revisions and amendments)
was 76 (median, 60; range, 19–212, 95% CI, 55–96) per
year and per committee, ranging from 13 exchanges for
phase I studies on drugs, through 19 for studies not inves-
tigating drugs and to 45 for studies on drugs other than
phase 1.
Revisions (major changes)
Revisions were requested for 555 (57%) protocols, but
only 181 (19%) required a second revision or more. A
revision could contain one or more points to be modified
by the investigator. In total 1438 points for modification
were cited (Table 4). Per protocol, the average number of
reasons per revision was 2.01 (the same reasons could
have required more than one revision). On average, one
reason (or less) was mentioned in 45% of revisions,
between one and two reasons in 25%, between two and
three 15%, and more than three reasons in 15% (data not
shown).
The main reasons for revisions were information to the
patient (28% of responses), consent modalities (18%),
inclusion criteria (8%), scientific factors (7%) and legal
and administrative requirements (6%). This global
Probability of approval from time of submission, according to  the initial decision of Research Ethics Committees Figure 1
Probability of approval from time of submission, according to 
the initial decision of Research Ethics Committees.
Table 3: Reasons for non-inclusion (167 protocols out of 1143)
n %
Approved in 1995 82 49
Withdrawn before approval 48 29
Rejected 16 9
Not within the scope of the law 12 7
Missing file 6 4
Approved in 1993 3 2
Time from submission (in months)
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Revision
Direct approval
Minor changes
1.0
Log-rank test
p<0.001
Direct approval
#to be approved : 3 0 1 4 263 31111 1100
# approved : 0 259 295 298 298 300 300 300 300 300 300 301 301
% approved : 08 69 89 9 9 99 99 99 99 9 9 99 9 1 0 0 1 0 0
Revision
#to be approved : 402 180 58 18 8 2 2 1 0 0 0 0 0
# approved : 0 222 344 384 394 400 400 401 402 402 402 402 402
% approved : 0 55 86 96 98 99 99 99 100 100 100 100 100
Minor changes
#to be approved : 266 223 88 40 23 13 10 9 7 5 1 1 0
# approved : 0 43 178 226 243 253 256 257 259 261 265 265 266
% approved : 01 66 78 5 9 19 59 69 79 7 9 89 99 9 1 0 0BMC Medical Ethics 2005, 6:9 http://www.biomedcentral.com/1472-6939/6/9
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ranking of reasons remained the same when considering
the sub-group of protocols with only one revision and the
sub-group of protocols with two revisions.
The ranking of reasons for protocols with three or more
revisions showed that legal and administrative points,
which were quite easy to solve, became less important,
falling from the 4th position (for protocols with one or
two revisions) to the 9th position. However, requests for
more specific methodological and statistical information,
which were more complex to solve, were more frequently
cited, rising from the 11th rank (for protocols with one or
two revisions) to 7th rank.
Amendments (after approval)
Over half of the investigators submitted no amendments
(57%), although few protocols were not implemented
and therefore could not have led to amendments. For the
416 protocols requiring at least one amendment, 875 rea-
sons were mentioned. An average of 1.2 reasons per
amendment was cited. A single reason was cited in 52% of
cases.
The main reasons for which protocols had to be modified
after approval were a change in the number of subjects to
be included (18%), a modification of inclusion criteria, a
modification of the timetable and changes in examina-
tions and treatments (Table 5). Regarding the legal and
administrative points cited, 43% concerned the update of
the list of investigators (data not shown). The number of
amendments submitted did not modify the ranking of
these reasons.
Additional information
As information on the progress of research is not manda-
tory, 81% of investigators did not send any further infor-
mation regarding their study. When they did it was mainly
to warn of the end (premature or normal) of the study
(30%), to declare adverse side effects (25%) and to inform
the committees of the intermediate or final study results
(18%).
RECs' administrative and expertise workload
The administrative staff panel estimated that administra-
tive tasks (registration, postal service, copying, classifica-
tion, letters, etc.) required 4.5 hours per initial protocol
recording, 4.5 hours per revision and 3.5 hours per
amendment (table 2). The experts panel estimated that
the expertise process required 6 hours per protocol, 3.25
hours per revision and 2.5 hours per amendment. This
was confirmed during the test on-site.
These figures show, per year and per month respectively,
an estimated administrative workload of 480.50/40 hours
and an estimated expertise workload of 453.25/38 hours
per REC (based on observed mean annual activity per
committee: 39 protocols, 39 revisions and 37 amend-
ments on average per REC and per year).
Protocol characteristics
Table 6 summarizes the main legal and administrative
characteristics of protocols and Table 7 the main scientific
and technical characteristics.
Legal and administrative characteristics
Sponsors were mainly pharmaceutical firms (64%). The
research setting was a tertiary teaching hospital in 55% of
cases; another 15% of protocols were conducted simulta-
neously in a tertiary teaching hospital and another type of
institution. The item "other" included other combina-
tions of these settings and also private offices, etc.
Technical characteristics
Drug evaluation was the object of research in 68% of
cases. For the research topic, the item "other" was cited in
8% of cases, usually for studies on genetics or vaccines,
i.e., other types of clinical trials. It was also pointed out
that participating RECs encountered problems in
reporting expected duration since 26% of the answers on
questionnaires neglected to mention this information.
Table 4: 1211 main reasons for revision before approval (out of a 
total of 1438)
n %
Patient information 399 27.7
Consent modalities 257 17.8
Inclusion criteria 116 8.1
Scientific prerequisite 105 7.3
Legal requirements 91 6.3
Sample size 71 4.9
Insurance 49 3.4
Information on treatments and exams 48 3.3
Study objectives 44 3.1
Information on methodology and statistics 31 2.2
Table 5: 657 main reasons for amendment after approval (out of 
a total of 875)
n%
Sample size 156 17.8
Inclusion criteria 143 16.3
Timetable 132 15.1
Treatment or exam modifications 89 10.2
Patient information 76 8.7
Legal and administrative modifications 61 7.0BMC Medical Ethics 2005, 6:9 http://www.biomedcentral.com/1472-6939/6/9
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Reasons for revisions varied according to investigators'
status (p < 0.0001; revisions on scientific prerequisite
were more frequent when investigators were neither pro-
fessor, nor assistant) and to place of research (p = 0.005;
revisions on inclusion criteria were more frequent when
research was conducted in phase I units) and reasons for
amendments according to sponsor (p = 0.01;
amendements on sample size were more frequent when
the sponsor was a public hospital), place of research (p =
0.03; amendments on treatment was more frequent for
research conducted in phase I units), study phase (p =
0.04; amendements concerned more often treatment for
phase I studies), study scope (p = 0.002; sample size was
more often modified when the study was national and
multicentre) and study duration (p = 0.001; amendments
were more often about treatment when study duration
was less than 2 months).
Multiple correspondence analysis
the scree test resulted in the selection of two axes explain-
ing 40% of the inertia. The modalities most contributing
to the construction of each axis were represented on figure
2. The first axis (dashed line) showed that study size dif-
ferentiated protocols the most. On one side were phase I
studies, protocols studying nutrition, cosmetics, protocols
on physiology, without direct benefit to the patient, of
short duration, single-centre studies, and those with fewer
than 20 patients expected (small studies). On the other
side were phase III studies, those with direct benefit to the
patient, more than 200 patients to be included, national
multicentre or international studies, and those with a
planned intermediate analysis (large studies).
The second axis separated descriptive studies sponsored
by the public sector from experimental studies on drugs,
mostly sponsored by private pharmaceutical firms.
Hierarchical clustering using Ward's minimum variance
This analysis yielded four clusters explaining 75% of the
variance. The first cluster included protocols on drug
testing (98% in this cluster vs. 68% in the global popula-
tion), with direct individual benefit, and phase II and
phase IV studies (respectively, 35% and 22% vs. 18% and
11%). Cluster 2 grouped phase I drugs trials (89% vs.
17%), without direct individual benefit (97% vs. 34%), in
a single centre (99% vs. 47%), lasting less than 2 months
and sponsored by pharmaceutical firms. Cluster 3 also
concerned drugs, but protocols were phase III studies
(64% vs. 23%), with direct individual benefit, multicentre
Table 6: Administrative characteristics of approved protocols
n %
Main investigator's status
Professor 567 58.1
Assistant 255 26.1
Other 154 15.8
Sponsor
Pharmaceutical firm 628 64.3
Tertiary teaching hospital 161 16.5
Industry 45 4.6
Other public organisation 102 10.4
Other 40 4.1
Place of research
Phase I specialized unit 162 16.6
Tertiary teaching hospital 543 55.6
Tertiary teaching hospital + private hospital 121 12.4
Tertiary teaching hospital + phase I specialized unit 18 1.8
Other 132 13.5
Table 7: Technical characteristics of approved protocols
n %
Topic
Drug 667 68.3
Phase I 163 24.4
Phase II 173 25.9
Phase III 226 33.9
Phase IV 105 15.7
Cosmetics and nutrition 50 5.1
Physiology 65 6.7
Medical equipment & prothesis 64 6.6
Surgical and/or diagnostic act 52 5.3
Other 78 8.0
Design
Descriptive, analytic 150 15.4
Experimental, non-randomized 319 32.7
Experimental, randomized 507 51.9
Scope
National-monocentric 463 47.4
National-multicentric 311 31.9
International 161 16.5
Not available 41 4.2
Expected sample size
Fewer than 21 patients 293 30.0
21 to 50 patients 251 25.7
51 to 150 patients 192 19.7
More than 150 patients 228 23.4
Not available 12 1.2
Expected duration
Less than 2 months 115 11.8
2 to 6 months 159 16.3
6 to 18 months 286 29.3
More than 18 months 163 16.7
Not available 253 25.9BMC Medical Ethics 2005, 6:9 http://www.biomedcentral.com/1472-6939/6/9
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and international (42% vs. 16%) and with a randomized
design (87% vs. 52%). Finally, cluster 4 grouped protocols
not evaluating drugs (89% vs. 32%), the studies were
descriptive (32% vs. 15%) and the sponsor was in the
public sector (58% vs. 27%).
Activity and workload in relation with protocol 
characteristics
We have linked the different clusters to the number of
revisions and amendments (table 8). The mean number
of revisions is homogeneous through clusters with a
minimum of 0.94 for cluster I and a maximum of 1.08 for
cluster III. Number of amendments varied more: from
0.46 for cluster II to 2.14 for cluster III.
The mean time spent per protocol (workload) was esti-
mated in each cluster, cluster III protocols are the most
time-consuming.
Time spent by each cluster was obtained by multiplying
number of protocols by mean time per protocol. At a
national level 31% of committees' time is spent for cluster
IV protocols, 28% for cluster III, 27% for cluster I and
13% for cluster II.
Discussion
On average, each REC studied 39 protocols, 39 revisions
and 37 amendments per year, representing an annual
workload of 934 hours (480.50 hours for administrative
tasks and 453.25 for expertise tasks, on a monthly basis
respectively 40 and 38 hours) including neither commit-
tee meetings nor training of the members since there is
too much variability across committees. Most protocols
evaluated drugs (68%), were experimental (85%) and
were monocentric (47%).
Graphical representation of multiple correspondence analysis on protocols characteristics* Figure 2
Graphical representation of multiple correspondence analysis on protocols characteristics*. *graphical representation of the 
modalities which contributes the most to the construction of axes 1 and 2.
Sponsor: industry
Sponsor: 
pharmaceutical
Setting:
 public 
hospital
Sponsor: public
Design: 
descriptive
Design: experimental, 
randomized
Topic: other
Topic: 
medical device
Topic: drugs
Investigator: 
professor
Amendments: 
at least 2
Amendment: none
Information:
at least 2
Scope: Multi-centre; 
international
Scope: national,
 single centre
Scope: national,
multicentric
With direct benedit
Without direct benefit
Interim analysis planned
Topic: cosmetics
Study phase: III Patients: less than 21
Patients: 
more than 200
Duration: less than 2 
months
Investigator: other
Topic: physiology
Study phase: I
Study phase: NA
Axis 1 
Axis 2 BMC Medical Ethics 2005, 6:9 http://www.biomedcentral.com/1472-6939/6/9
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The main advantage of our study is to have collected
exhaustive information for half of French RECs over a full
year (whether or not the principal investigator was lost to
follow-up). Moreover, homogeneous data collection was
guaranteed by the initial training followed by research
assistants. The choice of the year 1994 was based on initial
studies conducted by the French Ministry of Health [14-
16] showing that on average six years were needed to
reach publication, and that some studies were still ongo-
ing eight years later. This choice enabled us to gather all
the information during the whole protocol's duration. To
our knowledge our study is the first to have evaluated the
workload and the activity of RECs for each protocol
through the collection of the number of revisions, amend-
ments and additional information. The combination
between 1994's activity data and 2004's workload assess-
ment is justified since committees' missions have
remained the same and there is no reason why the regis-
tration or the expert evaluation should take more or less
time in 1994 compared to 2004. A 2001 French Senate
report [17] showed similarities across years in the number
of protocols evaluated by French RECs (total number of
protocol, type of research,...). Moreover, this would make
more sense to use the current procedure and workload
(2004) rather than the old ones (1994). To our mind, this
evaluation was closest to the reality, since a retrospective
cohort was mandatory to evaluate characteristics and fate
of biomedical protocols, whereas retrospective data col-
lection was not possible to assess workload.
Moreover the French law is broader than EC 2001/20
European Directive [6], since it aims to protect human
beings in all biomedical research (drugs, biomedical
devices, physiology, vaccines,...), and therefore the proto-
cols included in our study are not only on drugs
evaluation.
The major difficulties encountered concerned definitions.
Although the law clearly defines what are direct approvals
and revisions, some RECs evocated direct approval with
revision and postponed approval without revision.
However this issue is not related to our study methods but
to a difficulty in understanding and putting into effect the
French law. Despite their training, research assistants had
difficulties to retrieve information on study design and to
categorise it. Some data were often missing in the proto-
cols, such as the expected duration.
The four articles previously published collected informa-
tion on only one or two ethics committees[1-4]. These
studies did not describe the general situation at a country
level and they provided information only when the inves-
tigator was not lost for follow-up. Only one study gave
information on RECs' activity [1], namely some informa-
tion on the number of new applications, correspondence,
decisions, and the number of meetings needed to obtain
approval were given.
One of our major results is that 46% of revisions con-
cerned patient information and consent.
The above article showed that when studies were condi-
tionally approved, deferred or rejected, most queries also
concerned the patient information leaflet (85%). But only
protocols with five or more centres were assessed;
consequently these protocols were not representative of
all biomedical research on human beings.
Table 8: Tendendy in characteristics of 976 protocols according to clusters defined by a hierarchical analysis
CLUSTER I CLUSTER II CLUSTER III CLUSTER IV
N2 8 0 1 4 4 2 0 9 3 4 3
Main characteristics -drug testing
-phase II
-pharmaceutical 
sponsor
-with direct benefit
-phase IV
-phase I
-without direct benefit
-investigator: other
-single centre
-less than 2 months
-international scope
-phase III
-more than 200 
patients
-drug testing
-with direct benefit
-not drugs
-public setting
-descriptive design
-public sponsor
-industrial sponsor
PER PROTOCOL ANOVA p-value
Mean number of 
revisions
0.94 1.05 1.08 0.98 0.70
Mean number of 
amendments
0.78 0.46 2.14 0.53 <0.0001
Estimated average 
time (initial evalution, 
revision, amendment)
22.5 21.4 31.7 21.3 <0.0001BMC Medical Ethics 2005, 6:9 http://www.biomedcentral.com/1472-6939/6/9
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A French report [17] also gave such information, but the
aim was more to point out problems of putting the law
into effect in France.
Almost all protocols anticipate recruitment in terms of
sample size rather than in terms of study duration. We
think that the first point shows compliance with good
clinical practices [18], and the latter expresses the need for
a better training of prime investigators for clinical research
study management and anticipation.
The workload theme in terms of numbers of protocols,
number of revisions and number of amendments is very
relevant since French RECs' members work for free during
or after their workday, and at least administrative and
financial support of the REC structure is obviously needed
in order to guarantee independence in each country. The
results of our study are fully supported by the
recommendations of the Ad Hoc advisory group on the
operation of NHS Research Ethics Committees [19], ask-
ing for independent opinion, managed operating system,
time recognition and protection, as well as finances.
Across countries, RECs may not have the same structure
(frequency of meetings, number of people involved in the
committee), the same remit (only studies with interven-
tion on human or also studies on physiology, for
instance) and the same functioning since the number of
protocols reported in the above article was very heteroge-
neous in the different countries. When looked at in terms
of protocols approved per year and per committee, clear
differences appeared: 110 protocols approved in the
multicentre REC of London [1], 158 protocols in Barce-
lona [4], 180 protocols in Oxford [2], 94 protocols in Syd-
ney [3] and on average 39 protocols in France.
It would be of great importance to launch a similar study
in more recent years and in other settings at country level
to see if things have changed, and if so in which way. Stud-
ies in different European countries will allow to collect
information which would be very useful to ease harmoni-
sation. It would also be interesting to launch a prospective
recording of all tasks and time needed on a random sam-
ple of committees.
Conclusion
Up to now, one study described the activity of one REC
specialised in multicentre trials and three other studies
were carried out on the fate of protocols approved by one
committee but nothing was known at a nation level.
Our study showed that 976 protocols were approved in
one year by half of the French RECs and that median
approval time ranges from 16 days (if no modification) to
48 days. Moreover, most protocols were carried out in
France only (79%) for drugs evaluation (68%)
Revisions before approval relates first and foremost to
patient information and consent modalities (46%). For a
protocol evaluation (first evaluation, revisions and
amendments), scientific and administrative workload var-
ied on average from 21.3 hours up to 31.7 hours accord-
ing to protocols' characteristics.
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